COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication

Editorial Material Allergy

The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVID-19 vaccines

Beatriz Cabanillas et al.

ALLERGY (2022)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Anaphylactic reactions to polyethylene glycol-containing bowel cleansing preparations after Moderna COVID-19 vaccination

Maximilian Schreiner et al.

ENDOSCOPY (2022)

Add to Collection

Letter Allergy

Hypersensitivity to the Moderna COVID-19 Vaccine Caused by Tromethamine: PEG Is Not Always the Culprit Excipient

T. Azenha Rama et al.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina

Dan-Yu Lin et al.

Summary: In a study conducted in North Carolina, Covid-19 vaccines were found to be highly effective in preventing hospitalization and death for up to 9 months after vaccination. The decrease in protection against infection over time was attributed to both declining immunity and the emergence of the delta variant.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Allergy

Safety of COVID-19 vaccination in patients with clonal mast cell disorders

Maria Ruano-Zaragoza et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

Add to Collection

Letter Allergy

COVID-19 vaccination in the setting of mastocytosis-Pfizer-BioNTech mRNA vaccine is safe and well tolerated

Nikolaos Lazarinis et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

Add to Collection

Article

The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis

Marharyta Sobczak et al.

Clinical and Molecular Allergy (2022)

Add to Collection

Article Immunology

Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses

Jeffrey A. Tomalka et al.

Summary: Host genetic and environmental factors play a significant role in vaccine-induced immune responses. Understanding and accounting for these factors are crucial for the development of effective vaccines against SARS-CoV-2.

NATURE IMMUNOLOGY (2022)

Add to Collection

Letter Anesthesiology

Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?

Lene H. Garvey et al.

BRITISH JOURNAL OF ANAESTHESIA (2021)

Add to Collection

Letter Allergy

mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis

Tiago Azenha Rama et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Dermatology

Assessing vaccination reactions in pediatric patients with maculopapular cutaneous mastocytosis

Maija L. Johansen et al.

Summary: Immunization compliance in the United States is declining, partially due to misinformation and fear. Recent data suggests a possible link between routine vaccinations and symptoms in cutaneous mastocytosis patients, but this has not been thoroughly explored in dermatology literature. Although reaction rates may be higher in some patients, they are usually mild.

PEDIATRIC DERMATOLOGY (2021)

Add to Collection

Review Allergy

Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation

Ludger Klimek et al.

Summary: Following the emergency use authorization of the mRNA-1273 vaccine, two mRNA vaccines have been used to prevent COVID-19, but reports of allergic reactions have surfaced in the UK, Canada, and the US. The culprit may be the PEG-2000 contained in both vaccines as a potential trigger.

ALLERGY (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof et al.

Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.

LANCET (2021)

Add to Collection

Letter Allergy

COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms

Matthew P. Giannetti et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Allergy

Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy

Alexander Troelnikov et al.

Summary: Patients with a history of PEG allergy showed positive skin test results after receiving the BNT162b2 vaccine, while traditional PEG skin testing yielded negative results for 2 out of 3 patients. One patient exhibited cross-reactivity to PEG and polysorbate, leading to co-sensitization to both the BNT162b2 and AZD1222 vaccines.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Allergy

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

Patrizia Bonadonna et al.

Summary: Mastocytosis patients can safely receive COVID-19 vaccination, with severe adverse reactions being rare. It is recommended to broadly use COVID-19 vaccination globally, with the exception of known or suspected allergy to vaccine constituents. Safety measures should be considered based on individual risk and overall situation in each case.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Allergy

Successful SARS-CoV-2 vaccine allergy risk management: The experience of a large Italian University Hospital

Giovanni Paoletti et al.

Summary: By implementing an allergy work-up protocol during the vaccination campaign, the number of patients avoiding SARS-CoV-2 vaccination due to allergies can be significantly reduced. This protocol effectively identifies and manages rare patients sensitized to PEGs and/or PS80.

WORLD ALLERGY ORGANIZATION JOURNAL (2021)

Add to Collection

Letter Allergy

COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: COVID-19 vaccine anaphylaxis: PEG or not?

Beatriz Cabanillas et al.

ALLERGY (2021)

Add to Collection

Letter Allergy

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!

Matthew S. Krantz et al.

ALLERGY (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer et al.

Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

Jake A. Ruddy et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Editorial Material Allergy

Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome

Rayan Kaakati et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Review Allergy

The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach

Matthew Greenhawt et al.

Summary: This study involved an international multidisciplinary group of experts to systematically investigate the incidence of anaphylaxis after SARS-CoV-2 vaccination and the accuracy of allergy testing tools. The research found a low incidence of anaphylaxis after SARS-CoV-2 vaccination and low sensitivity of polyethylene glycol skin testing, but high specificity. Recommendations were made for vaccination for individuals without a history of severe allergic reactions and shared decision-making with an allergy specialist for those with a history of severe allergic reactions. Further research is recommended to clarify the utility of testing in individuals potentially allergic to SARS-CoV-2 vaccines or their excipients.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Review Allergy

Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

Theo Gulen et al.

Summary: Research on mast cell activation and syndromes has advanced in recent years, but there is ongoing debate about diagnostic and classification criteria, highlighting the importance of applying consensus criteria to ensure accurate diagnosis and treatment.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Letter Hematology